Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.31 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17434126 | 0.87 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL10324344 | 0.83 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL31751868 | 0.83 | — | — | |
| SCHEMBL2002035 | 0.82 | MEN1 (0.36) | MEN1KMT2ACES2CES1 | |
| SCHEMBL2422810 | 0.80 | MET (0.36) | MEN1KMT2A | |
| SCHEMBL30311696 | 0.80 | PDE2A (0.33) | MEN1KMT2A | |
| SCHEMBL25015121 | 0.78 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL28363112 | 0.77 | PDE2A (0.37) | MEN1KMT2A | |
| SCHEMBL31378595 | 0.76 | — | — | |
| SCHEMBL22905071 | 0.75 | PDE2A (0.34) | MEN1KMT2ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250263410-A1 | NK3 MODULATORS AND USES THEREOF | KALLYOPE, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12281114-B2 | NK3 modulators and uses thereof | KALLYOPE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250092009-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-03-20 | — | — | US | disclosed |
| WO-2024220539-A1 | NK3 MODULATORS AND USES THEREOF | KALLYOPE, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-112424181-B | Substituted condensed thiophenes as STING modulators | 希泰克斯特私人有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3793988-B1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-11-15 | — | — | EP | disclosed |
| EP-3793988-B1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-11-15 | — | — | EP | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| EP-2374788-B1 | INDANYL COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2374788-A1 | INDANYL COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263410-A1 | NK3 MODULATORS AND USES THEREOF | TAC3, TACR3, TACR2 | MEN1 1850/4885KMT2A 2777/4885CES2 4101/4885 |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | MEN1 1930/4885KMT2A 1206/4885CES2 2409/4885 |
| US-12281114-B2 | NK3 modulators and uses thereof | TAC3, TACR3, TACR2 | MEN1 1850/4885KMT2A 2777/4885CES2 4101/4885 |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | MEN1 1659/4885KMT2A 2928/4885CES2 880/4885 |
| US-20110319359-A1 | INDANYL COMPOUNDS | RYR2, ORAI1, CASR | MEN1 2944/4885KMT2A 4655/4885CES2 2526/4885 |
| US-20250092009-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | MEN1 1930/4885KMT2A 1206/4885CES2 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.